China's huge market potential vaccine – Mosaic texture – Stone texture

Avian flu, SARS, influenza, epidemic prevention and control of global challenges, but also to vaccine development and production companies to the huge market. In recent years, the global vaccine market has grown rapidly, but also in the pharmaceutical market share of only 2.5%, there is still tremendous room for growth. The scale of the global vaccine market in 2006 was about 14.177 billion U.S. dollars, an increase of 18% to projections, the global vaccine market in 2007 was 16.729 billion U.S. dollars, 2008 was 19.741 billion U.S. dollars. The future of the global vaccine market is expected to maintain annual growth of 10%.
Global vaccine market concentration is very high. It is understood that there are around 20 companies were identified by the WHO as the vaccine manufacturers, the largest of five multinational companies are GlaxoSmithKline, Sanofi – Pasteur, Merck, Wyeth Pharmaceuticals, Novartis pharmaceuticals, vaccines of which the first four companies in 2007 had sales of more than 2 billion U.S. dollars, which together account for about 85% of global market share.
At present, residents in vaccination rates still very low. To influenza vaccine, for example, China's vaccination rate of less than 2%, while European and American developed countries to achieve universal vaccination rate of 20% to 30%, Canada is to achieve a vaccination rate of 45%. With the recent changes in the epidemic of influenza vaccination and awareness of the general population increase, China's population will gradually increase vaccination rates, so the vaccine market in China has great potential.
Becoming a class of vaccine from the market competition
China's vaccine market size in 2009 was about 9.02 billion yuan. The next few years, the domestic vaccine market compound annual growth rate of more than 15%.
Quantitatively, a class of vaccine in China in 2009 accounted for 80% of the vaccine market is about; but sales of view, a class of vaccines in China only accounts for 36% of the vaccine market. A class of vaccine market in China mainly by domestic production and supply of six Institute of Biological Products, its share of a class of more than 80% of the vaccine market. Pharmaceutical and Biological Products from China by the batch release point of view, a very small number of private enterprises to enter the hepatitis B vaccine and live attenuated JE vaccine supply market, but as part of the Type II vaccine be included in the scope of a class of vaccine, expected in the future of private enterprises a class of vaccine will be further beachhead market.
In addition, foreign-funded enterprises may enter a class of vaccine market in China. According to December 1, 2007 from the implementation of the "Foreign Investment Industrial Guidance Catalogue (2007 Amendment)", BCG and polio vaccines have emerged to encourage foreign investment in the industry directory; national immunization programs that were originally within the vaccine local businesses, "city" and its borders have begun to relax. Overall, the future vaccine market in China for a class of vaccine from the state-owned enterprises monopolize the situation is likely to be broken.
Type II vaccine market growth rate significantly
In recent years, China's Type II vaccine market growth significantly, the market in 2006 to 27.7 billion yuan to 5.795 billion yuan in 2009, the annual compound growth rate of 28%. China Type II vaccine rabies vaccine, influenza vaccine, meningitis vaccine (except A group A group C meningitis vaccine and meningitis vaccine group), b Hib conjugate vaccine, chickenpox, pneumonia, encephalitis inactivated vaccine as the main species. Judging from the number of Release of 2009, there is a large market size of rabies vaccines, influenza vaccines (including H1N1), b Hib conjugate vaccine, meningitis vaccine.
Along with "vaccine distribution and vaccination regulations," the implementation and operation of eligible candidates for Type II vaccine was expanded, the vaccine business entities of diverse Jiang Shi vaccine market competition tends to be open, fair, but at the same time, competition in the vaccine market intensifying.
Rely on foreign sales, management, research, capital and other aspects of the advantages in China has established its own agency, to enter the vaccine market in China; same time, China's Li Liang Qi Ye vaccines are also constantly expanding through independent innovation, Yanfa new Chan Pin, combination of cost and market advantages, domestic vaccine market and increase their competitiveness. The number of private enterprises account for Type II vaccine batch release of vaccines share growth in 2009 has reached 49%, sales revenue from 32% in 2006 to 45% in 2009. Release of the number of foreign-funded enterprises accounted for Type II vaccine vaccine proportion of the total from 2006 to 2009 increased 10% to 17%, but sales remained at 25%. Expected future domestic enterprises in foreign competition in mature vaccine will occupy a certain advantage, but in some major diseases such as AIDS, influenza, dengue virus, HPV and other vaccines are relatively weak competitiveness.

I am an expert from, while we provides the quality product, such as Mosaic texture , Stone texture, decorative wall panel manufacturer,and more.

Processing your request, Please wait....

Leave a Reply